This analysis covers Qoniq's ideal customer profile within pharmaceutical and biotech Medical Affairs teams, identifying segments where evidence synthesis at scale is a critical pain point.
Segments were chosen based on the intersection of high data volume (e.g., FDA submissions, clinical trial registries), acute regulatory pressure, and the ability to craft messages referencing specific public databases.
When manual literature surveillance misses a key study supporting a new indication, a 6-month regulatory delay can cost $500M+ in peak sales for a blockbuster drug. The FDA's accelerated review timelines make comprehensive evidence capture non-negotiable.
Adverse event signals buried in post-market publications can go undetected for months, leading to expanded warnings or withdrawal. A single missed signal that triggers a class-labeling change can reduce a drug's market by 30% or more.
| # | Segment | TAM | Pain | Conversion | Score |
|---|---|---|---|---|---|
| 1 | Large Pharma Blockbuster Drug Medical Affairs Teams NAICS 325412 · US/UK/DE/CH · ~50 companies | ~50 | 0.90 | 15% | 88 / 100 |
| 2 | Mid-Size Pharma with Pipeline Assets in Phase III NAICS 325412 · US/UK/DE · ~200 companies | ~200 | 0.85 | 12% | 82 / 100 |
| 3 | Specialty Biotech with Orphan Drug Designations NAICS 325412 · US/UK/FR · ~150 companies | ~150 | 0.80 | 10% | 78 / 100 |
| 4 | CROs with Medical Affairs Outsourcing Units NAICS 541714 · US/UK · ~80 companies | ~80 | 0.75 | 8% | 74 / 100 |
| 5 | Digital Health Companies with FDA-Cleared Devices NAICS 334510 · US/UK · ~200 companies | ~200 | 0.70 | 6% | 71 / 100 |
The pain. For a blockbuster drug, manual publication screening misses up to 40% of safety signals and competitive intelligence, risking delayed regulatory submissions costing $1M+/day and FDA warning letters for incomplete pharmacovigilance.
How to identify them. Use the FDA's Drugs@FDA database to identify companies with approved blockbuster drugs (>$1B annual revenue) and cross-reference with the EMA's European public assessment reports (EPARs) for drugs with active post-authorization safety studies. Filter for companies with >10,000 annual publications in their therapy area using PubMed search results.
Why they convert. The 2023 FDA guidance on postmarket safety surveillance explicitly requires systematic literature review, and manual processes fail to meet these standards at scale. A single missed safety signal can trigger a class-labeling change that costs $100M+ in lost sales.
The pain. Mid-size pharma with Phase III assets must monitor competitive pipelines and emerging safety data across 5,000+ publications annually, but lack the dedicated teams of large pharma. This leads to missed clinical trial enrollment delays and inaccurate comparator data in regulatory filings.
How to identify them. Query ClinicalTrials.gov for Phase III trials sponsored by companies with <$10B annual revenue, then check SEC EDGAR filings (10-K) for mentions of 'Medical Affairs' or 'publication planning'. Filter for companies with 3-10 pipeline assets in Phase II/III using PharmaProjects (Citeline) database.
Why they convert. Regulatory submission timelines for NDA/BLA are fixed, so any delay in synthesizing competitive intelligence directly pushes back revenue by months. The ROI of avoiding a single competitor-missed signal is 10x the annual cost of Qoniq.
The pain. Orphan drug teams must track all published literature on their rare disease, often <500 publications per year, but manual review still misses key patient-reported outcomes or natural history data that FDA requires for approval. This causes costly resubmissions or additional clinical trials.
How to identify them. Use the FDA Orphan Drug Designations database to find companies with active orphan designations, then cross-reference with the EMA's Orphan Medicinal Product designation list. Filter for companies with <500 employees using Crunchbase or PitchBook.
Why they convert. Orphan drug developers face compressed timelines (7-year market exclusivity) and need every publication insight to optimize their clinical development plan. Qoniq's AI can automatically flag emerging natural history studies that are critical for FDA breakthrough therapy designations.
The pain. CROs that offer outsourced Medical Affairs services must manage publication surveillance for multiple pharma clients, each with different therapy areas, but their manual processes don't scale. This leads to client churn when they fail to meet SLAs for signal detection or competitive monitoring.
How to identify them. Search the FDA's Bioresearch Monitoring Information System (BMIS) for CROs with active clinical investigator lists, then filter by companies that advertise Medical Affairs services on their website using LinkedIn company pages. Cross-check with the Association of Clinical Research Organizations (ACRO) member directory.
Why they convert. CROs win contracts based on efficiency and accuracy, and Qoniq's automation lets them serve 3x more clients with the same headcount. A single lost contract due to missed publications costs $500K+ in annual revenue.
The pain. Digital health companies with FDA-cleared devices must monitor post-market literature for adverse events and real-world evidence, but their small teams are overwhelmed by the 1,000+ annual publications on digital therapeutics. This risks FDA 510(k) reclassification or recalls.
How to identify them. Use the FDA 510(k) Premarket Notification database to find companies with recent clearances for software-as-medical-device (SaMD) products, then filter by those with <100 employees using the UK Companies House register or US SEC EDGAR. Cross-check with the Digital Therapeutics Alliance member list.
Why they convert. The FDA's Digital Health Center of Excellence requires continuous safety monitoring, and manual review is impossible for small teams. Qoniq's AI can automatically flag adverse event signals from PubMed and social media, preventing costly recall actions.
| Database | Country | Reliability | What it reveals | Used in |
|---|---|---|---|---|
| Drugs@FDA | US | HIGH | NDA numbers, approval dates, postmarketing requirements and deadlines for approved drugs. | Play 1 |
| FDA Bioresearch Monitoring Information System | US | HIGH | FDA inspection dates and enforcement actions for clinical investigators and sponsors. | Play 1 |
| LinkedIn Company Pages | Global | MEDIUM | Company tech stack, employee count, and decision-maker titles. | Play 1 |
| Crunchbase | Global | MEDIUM | Funding rounds, key executives, and company descriptions. | Play 1 |
| FDA Orphan Drug Designations | US | HIGH | List of drugs with orphan designation, including sponsor and indication. | Play 1 |
| FDA 510(k) Premarket Notification Database | US | HIGH | Medical device clearances with manufacturer and submission date. | Play 1 |
| ACRO Member Directory | US | HIGH | Member CROs and their services, useful for identifying pharma partners. | Play 1 |
| EMA Orphan Medicinal Product Designations | EU | HIGH | EU orphan designations with sponsor and therapeutic area. | Play 1 |
| EMA European Public Assessment Reports | EU | HIGH | Approval history, safety updates, and post-authorization measures for EU drugs. | Play 1 |
| PharmaProjects (Citeline) | Global | HIGH | Drug pipeline status, clinical trial phases, and company profiles. | Play 1 |
| PubMed | US | HIGH | Published biomedical literature, searchable by drug, disease, and author. | Play 1 |
| ClinicalTrials.gov | US | HIGH | Clinical trial records including sponsor, phase, and results. | Play 1 |
| SEC EDGAR | US | HIGH | Public company filings (10-K, 8-K) revealing revenue, risks, and regulatory updates. | Play 1 |
| UK Companies House | UK | HIGH | Company registration details, financials, and director names for UK entities. | Play 1 |
| Digital Therapeutics Alliance Member Directory | Global | HIGH | Member companies developing digital therapeutics, potential partners or competitors. | Play 1 |